KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Convertible Debt (2016 - 2022)

Historic Convertible Debt for Supernus Pharmaceuticals (SUPN) over the last 10 years, with Q1 2022 value amounting to $400.4 million.

  • Supernus Pharmaceuticals' Convertible Debt rose 938.26% to $400.4 million in Q1 2022 from the same period last year, while for Mar 2022 it was $400.4 million, marking a year-over-year increase of 938.26%. This contributed to the annual value of $379.3 million for FY2021, which is 483.79% up from last year.
  • According to the latest figures from Q1 2022, Supernus Pharmaceuticals' Convertible Debt is $400.4 million, which was up 938.26% from $379.3 million recorded in Q4 2021.
  • Supernus Pharmaceuticals' Convertible Debt's 5-year high stood at $400.4 million during Q1 2022, with a 5-year trough of $318.2 million in Q1 2018.
  • In the last 5 years, Supernus Pharmaceuticals' Convertible Debt had a median value of $349.2 million in 2020 and averaged $350.9 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Convertible Debt skyrocketed by 2176956.52% in 2018 and then surged by 474.04% in 2019.
  • Over the past 5 years, Supernus Pharmaceuticals' Convertible Debt (Quarter) stood at $329.5 million in 2018, then grew by 4.77% to $345.2 million in 2019, then grew by 4.8% to $361.8 million in 2020, then grew by 4.84% to $379.3 million in 2021, then grew by 5.57% to $400.4 million in 2022.
  • Its Convertible Debt stands at $400.4 million for Q1 2022, versus $379.3 million for Q4 2021 and $374.8 million for Q3 2021.